• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.69% Nasdaq Up2.12%

    Anika Therapeutics Inc. (ANIK)

    -NasdaqGS
    38.13 1.49(4.07%) Dec 17, 4:00PM EST
    |Pre-Market : 38.52 Up 0.42 (1.10%) 8:00AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Anika Therapeutics Inc.
    32 Wiggins Avenue
    Bedford, MA 01730
    United States - Map
    Phone: 781-457-9000
    Fax: 781-305-9720
    Website: http://www.anikatherapeutics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:102

    Business Summary 

    Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company’s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packin; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, AnikaVisc, and AnikaVisc Plus that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation; and veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. markets its products through a network of distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Anika Therapeutics Inc.

    Corporate Governance 
    Anika Therapeutics Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 10. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Charles H. Sherwood Ph.D., 67
    Chief Exec. Officer, Pres and Director
    1.15M911.00K
    Ms. Sylvia Cheung , 39
    Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.
    414.00K0.00
    Mr. Frank J. Luppino , 46
    Chief Operating Officer
    N/AN/A
    Dr. Edward S. Ahn Ph.D.,
    Chief Technology & Strategy Officer
    N/AN/A
    Mr. Steven Cyr ,
    VP of HR
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders